Latest News & Features
Americas
Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a US District Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction. 4 September 2017
Americas
The California Life Sciences Association (CLSA), an advocacy group, has added six new members to its board of directors. 1 September 2017
Americas
Bayer HealthCare has filed a lawsuit against Nektar Therapeutics and Baxalta seeking a declaration that a treatment for haemophilia A does not infringe their patent. 31 August 2017
Asia-Pacific
The Australian government has rejected proposals by the Productivity Commission regarding extending the length of pharmaceutical patents. 31 August 2017
Americas
The Federal Trade Commission has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business. 31 August 2017
Big Pharma
The practical implications of Brexit, including on the Unified Patent Court, were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event. 31 August 2017
Big Pharma
The UK government has committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry. 30 August 2017
Americas
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner. 30 August 2017
Asia
AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease. 29 August 2017
Americas
Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors. 29 August 2017